1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
2Genetic Pathology Evaluation Center (GPEC), Vancouver, BC, Canada
3Department of Pathology, University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, Targu Mures, Romania
4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
5Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
6Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada
© 2020 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Ethics Statement
All procedures performed in the current study were approved by the Institutional Review Board (IRB) (H18-01652, October 1, 2018) in accordance with the 1964 Helsinki declaration and its later amendments. Formal written informed consent was not required with a waiver by the appropriate IRB.
Author contributions
Conceptualization: LH, DH. Data curation: HR, JP. Formal analysis: HR, LH. Investigation: CC, MT. Methodology: CC, MT. Supervision: LH, DH. Validation: LH. Visualization: HR, LH. Writing—original draft: HR, LH. Writing—review & editing: SS, RS, LH. Approval of final manuscript: all authors.
Conflicts of Interest
The authors declare that they have no potential conflicts of interest.
Funding Statement
This study has supported by the Carraressi Foundation, Sumiko Kobayashi Marks Memorial Fund, OVCare and the UBC & VGH Hospital Foundations.
Concordant |
Discordanta |
Unclassifiable | Overall concordance, n (%) | |||
---|---|---|---|---|---|---|
HPVA/HPV+ | NHPVA/HPV– | HPVA/HPV– | NHPVA/HPV+ | |||
Original review | 87 | 16 | 7 | 1 | 0 | 103/111 (92.8) |
Expert review | 87 | 20 | 1 | 1 | 2 | 107/111 (96.4) |
|
||||||
HPVA/p16+ | NHPVA/p16– | HPVA/p16– | NHPVA/p16+ | |||
|
||||||
Original review | 90 | 16 | 4 | 1 | 0 | 106/111 (95.4) |
Expert review | 87 | 19 | 1 | 2 | 2 | 106/111 (95.4) |